Target Indication：
For the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.
Strength：
4 mg/0.1 mL
Dosage Form:
Nasal Spray, Single-dose
Timeline：ANDA submission- Q2. 2026 in US, launch into US market-Q4.2027.
The FP facility is specialized in researching and manufacturing nasal sprays, inhalation solutions, DPIs, MDIs, delivery devices, etc.
